Emodin promotes the arrest of human lymphoma Raji cell proliferation through the UHRF1‑DNMT3A‑∆Np73 pathways

Lin,Yun; Chen,Weiming; Wang,Zhihong; Cai,Pengwei

doi:10.3892/mmr.2017.7423

Emodin promotes the arrest of human lymphoma Raji cell proliferation through the UHRF1‑DNMT3A‑∆Np73 pathways

Authors:
- Yun Lin
- Weiming Chen
- Zhihong Wang
- Pengwei Cai
View Affiliations

Affiliations: Department of Hematology, Fujian Provincial Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350108, P.R. China, Department of Clinical Laboratory, Fujian Provincial Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350108, P.R. China
Published online on: September 5, 2017 https://doi.org/10.3892/mmr.2017.7423
Pages: 6544-6551
Copyright: © Lin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Emodin is an active constituent found in the roots and rhizomes of numerous Chinese medicinal herbs. It exerts antitumor activity against Dalton's lymphoma in vivo, although the detailed mechanisms by which emodin induces apoptosis remains to be elucidated. The present study aimed to analyze the mechanisms underlying the response to emodin treatment. Using lymphoma Raji cells, an emodin‑induced cell proliferating inhibition model was first established, then flow cytometry, western blotting, reverse transcription‑quantitative polymerase chain reaction and luciferase reporter assay were performed. It was found that emodin decreased the percentage of Raji cell viability, induced apoptosis, and increased the activation of caspase 3, caspase 9 and poly (ADP‑ribose) polymerase through the downregulation of ubiquitin‑like protein containing PHD and RING domains 1 (UHRF1). The emodin‑induced downregulation of UHRF1 led to an increase in the level of DNA methyltransferase 3A, which in turn inhibited the activity of p73 promoter 2 and decreased the levels of NH2‑terminally truncated dominant‑negative p73. The treatment of Raji cells with emodin combined with doxorubicin led increased cell death of Raji cells, indicating that emodin may sensitize Raji cells to doxorubicin‑induced apoptosis.

View Figures

View References

1	Zheng ZH, Hu JD, Chen YY, Lian XL, Zheng HY, Zheng J and Lin MH: Effect of emodin on proliferation inhibition and apoptosis induction in leukemic K562 cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 17:1434–1438. 2009.(In Chinese). PubMed/NCBI
2	Lai MY, Hour MJ, Wing-Cheung Leung H, Yang WH and Lee HZ: Chaperones are the target in aloe-emodin-induced human lung nonsmall carcinoma H460 cell apoptosis. Eur J Pharmacol. 573:1–10. 2007. View Article : Google Scholar : PubMed/NCBI
3	Lai JM, Chang JT, Wen CL and Hsu SL: Emodin induces a reactive oxygen species-dependent and ATM-p53-Bax mediated cytotoxicity in lung cancer cells. Eur J Pharmacol. 623:1–9. 2009. View Article : Google Scholar : PubMed/NCBI
4	Pastor DM, Irby RB and Poritz LS: Tumor necrosis factor alpha induces p53 up-regulated modulator of apoptosis expression in colorectal cancer cell lines. Dis Colon Rectum. 53:257–263. 2010. View Article : Google Scholar : PubMed/NCBI
5	Yang SX, Steinberg SM, Nguyen D and Swain SM: p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer. Int J Oncol. 38:1445–1452. 2011. View Article : Google Scholar : PubMed/NCBI
6	Goel A, Fuerst F, Hotchkiss E and Boland CR: Selenomethionine induces p53 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cancer Biol Ther. 5:529–535. 2006. View Article : Google Scholar : PubMed/NCBI
7	Tu SP, Chi AL, Ai W, Takaishi S, Dubeykovskaya Z, Quante M, Fox JG and Wang TC: p53 inhibition of AP1-dependent TFF2 expression induces apoptosis and inhibits cell migration in gastric cancer cells. Am J Physiol Gastrointest Liver Physiol. 297:G385–G396. 2009. View Article : Google Scholar : PubMed/NCBI
8	Yang L, Zhou Y, Li Y, Zhou J, Wu Y, Cui Y, Yang G and Hong Y: Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells. Cancer Lett. 357:520–526. 2015. View Article : Google Scholar : PubMed/NCBI
9	Machado-Silva A, Perrier S and Bourdon JC: p53 family members in cancer diagnosis and treatment. Semin Cancer Biol. 20:57–62. 2010. View Article : Google Scholar : PubMed/NCBI
10	Basu S and Murphy ME: p53 family members regulate cancer stem cells. Cell Cycle. 15:1403–1404. 2016. View Article : Google Scholar : PubMed/NCBI
11	Becker K, Pancoska P, Concin N, Heuvel K Vanden, Slade N, Fischer M, Chalas E and Moll UM: Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancers. Int J Oncol. 29:889–902. 2006.PubMed/NCBI
12	Castillo J, Goñi S, Latasa MU, Perugorría MJ, Calvo A, Muntané J, Bioulac-Sage P, Balabaud C, Prieto J, Avila MA and Berasain C: Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform DeltaEx2p73 in human hepatocellular tumors. Gastroenterology. 137:1805–15, e1–4. 2009. View Article : Google Scholar : PubMed/NCBI
13	Marrazzo E, Marchini S, Tavecchio M, Alberio T, Previdi S, Erba E, Rotter V and Broggini M: The expression of the DeltaNp73beta isoform of p73 leads to tetraploidy. Eur J Cancer. 45:443–453. 2009. View Article : Google Scholar : PubMed/NCBI
14	Mendoza M, Mandani G and Momand J: The MDM2 gene family. Biomol Concepts. 5:9–19. 2014. View Article : Google Scholar : PubMed/NCBI
15	Momand J, Villegas A and Belyi VA: The evolution of MDM2 family genes. Gene. 486:23–30. 2011. View Article : Google Scholar : PubMed/NCBI
16	Madhumalar A, Lee HJ, Brown CJ, Lane D and Verma C: Design of a novel MDM2 binding peptide based on the p53 family. Cell Cycle. 8:2828–2836. 2009. View Article : Google Scholar : PubMed/NCBI
17	Johnson J, Lagowski J, Lawson S, Liu Y and Kulesz-Martin M: p73 expression modulates p63 and Mdm2 protein presence in complex with p53 family-specific DNA target sequence in squamous cell carcinogenesis. Oncogene. 27:2780–2787. 2008. View Article : Google Scholar : PubMed/NCBI
18	Guo W, Ahmed KM, Hui Y, Guo G and Li JJ: siRNA-mediated MDM2 inhibition sensitizes human lung cancer A549 cells to radiation. Int J Oncol. 30:1447–1452. 2007.PubMed/NCBI
19	Yu H, Zou Y, Jiang L, Yin Q, He X, Chen L, Zhang Z, Gu W and Li Y: Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles. Biomaterials. 34:2738–2747. 2013. View Article : Google Scholar : PubMed/NCBI
20	Ma J, Peng J, Mo R, Ma S, Wang J, Zang L, Li W and Fan J: Ubiquitin E3 ligase UHRF1 regulates p53 ubiquitination and p53-dependent cell apoptosis in clear cell Renal Cell Carcinoma. Biochem Biophys Res Commun. 464:147–153. 2015. View Article : Google Scholar : PubMed/NCBI
21	Alhosin M, Abusnina A, Achour M, Sharif T, Muller C, Peluso J, Chataigneau T, Lugnier C, Schini-Kerth VB, Bronner C and Fuhrmann G: Induction of apoptosis by thymoquinone in lymphoblastic leukemia Jurkat cells is mediated by a p73-dependent pathway which targets the epigenetic integrator UHRF1. Biochem Pharmacol. 79:1251–1260. 2010. View Article : Google Scholar : PubMed/NCBI
22	Colley SM, Iyer KR and Leedman PJ: The RNA coregulator SRA, its binding proteins and nuclear receptor signaling activity. IUBMB Life. 60:159–164. 2008. View Article : Google Scholar : PubMed/NCBI
23	Dai C, Shi D and Gu W: Negative regulation of the acetyltransferase TIP60-p53 interplay by UHRF1 (ubiquitin-like with PHD and RING finger domains 1). J Biol Chem. 288:19581–19592. 2013. View Article : Google Scholar : PubMed/NCBI
24	Liang CC and Cohn MA: UHRF1 is a sensor for DNA interstrand crosslinks. Oncotarget. 7:3–4. 2016. View Article : Google Scholar : PubMed/NCBI
25	Delagoutte B, Lallous N, Birck C, Oudet P and Samama JP: Expression, purification, crystallization and preliminary crystallographic study of the SRA domain of the human UHRF1 protein. Acta Crystallogr Sect F Struct Biol Cryst Commun. 64:922–925. 2008. View Article : Google Scholar : PubMed/NCBI
26	Bronner C, Achour M, Arima Y, Chataigneau T, Saya H and Schini-Kerth VB: The UHRF family: Oncogenes that are drugable targets for cancer therapy in the near future? Pharmacol Ther. 115:419–434. 2007. View Article : Google Scholar : PubMed/NCBI
27	Singh KB and Trigun SK: Apoptosis of Dalton's lymphoma due to in vivo treatment with emodin is associated with modulations of hydrogen peroxide metabolizing antioxidant enzymes. Cell Biochem Biophys. 67:439–449. 2013. View Article : Google Scholar : PubMed/NCBI
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
29	Poupot M, Pont F and Fournié JJ: Profiling blood lymphocyte interactions with cancer cells uncovers the innate reactivity of human gamma delta T cells to anaplastic large cell lymphoma. J Immunol. 174:1717–1722. 2005. View Article : Google Scholar : PubMed/NCBI
30	Gujral S, Polampalli SN, Badrinath Y, Kumar A, Subramanian PG, Nair R, Gupta S, Sengar M and Nair C: Immunophenotyping of mature B-cell non Hodgkin lymphoma involving bone marrow and peripheral blood: Critical analysis and insights gained at a tertiary care cancer hospital. Leuk Lymphoma. 50:1290–1300. 2009. View Article : Google Scholar : PubMed/NCBI
31	Emmrich S, Wang W, John K, Li W and Pützer BM: Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo. Mol Cancer. 8:612009. View Article : Google Scholar : PubMed/NCBI
32	Lau LM, Wolter JK, Lau JT, Cheng LS, Smith KM, Hansford LM, Zhang L, Baruchel S, Robinson F and Irwin MS: Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma. Oncogene. 28:2024–2033. 2009. View Article : Google Scholar : PubMed/NCBI
33	Graça I, Sousa EJ, Baptista T, Almeida M, Ramalho-Carvalho J, Palmeira C, Henrique R and Jerónimo C: Anti-tumoral effect of the non-nucleoside DNMT inhibitor RG108 in human prostate cancer cells. Curr Pharm Des. 20:1803–1811. 2014. View Article : Google Scholar : PubMed/NCBI
34	Hopfer O, Komor M, Koehler IS, Freitag C, Schulze M, Hoelzer D, Thiel E and Hofmann WK: Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms. Leuk Res. 33:434–442. 2009. View Article : Google Scholar : PubMed/NCBI
35	Liu K, Zhan M and Zheng P: Loss of p73 expression in six non-small cell lung cancer cell lines is associated with 5′CpG island methylation. Exp Mol Pathol. 84:59–63. 2008. View Article : Google Scholar : PubMed/NCBI
36	Watanabe T, Huang H, Nakamura M, Wischhusen J, Weller M, Kleihues P and Ohgaki H: Methylation of the p73 gene in gliomas. Acta Neuropathol. 104:357–362. 2002.PubMed/NCBI
37	Lai J, Nie W, Zhang W, Wang Y, Xie R, Wang Y, Gu J, Xu J, Song W, Yang F, et al: Transcriptional regulation of the p73 gene by Nrf-2 and promoter CpG methylation in human breast cancer. Oncotarget. 5:6909–6922. 2014. View Article : Google Scholar : PubMed/NCBI
38	Rizzo MG, Giombini E, Diverio D, Vignetti M, Sacchi A, Testa U, Lo-Coco F and Blandino G: Analysis of p73 expression pattern in acute myeloid leukemias: Lack of DeltaN-p73 expression is a frequent feature of acute promyelocytic leukemia. Leukemia. 18:1804–1809. 2004. View Article : Google Scholar : PubMed/NCBI
39	Kawano S, Miller CW, Gombart AF, Bartram CR, Matsuo Y, Asou H, Sakashita A, Said J, Tatsumi E and Koeffler HP: Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood. 94:1113–1120. 1999.PubMed/NCBI
40	El-Osta A: DNMT cooperativity-the developing links between methylation, chromatin structure and cancer. Bioessays. 25:1071–1084. 2003. View Article : Google Scholar : PubMed/NCBI
41	Peng DF, Kanai Y, Sawada M, Ushijima S, Hiraoka N, Kitazawa S and Hirohashi S: DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis. 27:1160–1168. 2006. View Article : Google Scholar : PubMed/NCBI
42	Liu X, Gao Q, Li P, Zhao Q, Zhang J, Li J, Koseki H and Wong J: UHRF1 targets DNMT1 for DNA methylation through cooperative binding of hemi-methylated DNA and methylated H3K9. Nat Commun. 4:15632013. View Article : Google Scholar : PubMed/NCBI
43	Sharif J, Muto M, Takebayashi S, Suetake I, Iwamatsu A, Endo TA, Shinga J, Mizutani-Koseki Y, Toyoda T, Okamura K, et al: The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature. 450:908–912. 2007. View Article : Google Scholar : PubMed/NCBI
44	Hu L, Li Z, Wang P, Lin Y and Xu Y: Crystal structure of PHD domain of UHRF1 and insights into recognition of unmodified histone H3 arginine residue 2. Cell Res. 21:1374–1378. 2011. View Article : Google Scholar : PubMed/NCBI